Research Article
Prevalence, Demographics, and Treatment Characteristics of Visual Impairment due to Diabetic Macular Edema in a Representative Canadian Cohort
Table 5
Treatment characteristics of patients with VI due to DME.
| | | Patients with VI due to DME () |
| | Average time to treatment (days) (mean ± SD) | | | Lag to second treatment (days) (mean ± SD) | |
| | Type | Focal | Diffuse |
| Number of patients
(%) | 114 (53%) | 101 (47%) |
| | Treatment type (% of all treatments recorded in patients’ charts)* |
| | Anti-VEGF monotherapy | 18.2% | 15.0% | | Intravitreal Triamcinolone Acetonide (IVTA) | 1.0% | 3.0% | | Other | 0.5% | 1.9% | | Laser mono | 69.3% | 53.3% | | Laser combo | | | | Laser—anti-VEGF | 7.8% | 12.1% | | Laser—IVTA | 3.1% | 15.0% |
|
|
*Some patients received more than one type of treatment; anti-VEGF: anti-vascular endothelial growth factor.
|
